Skip to content
OpenCapital
Get started

Harmony Biosciences Holdings, Inc. HRMY EV / EBITDA

EV / EBITDA at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
17.6×-4.0×
Alkermes logo
AlkermesALKS
30.8×+18.8×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
41.5×—
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
38.4×+27.9×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.4×-1.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.98B-14.9%
Enterprise value$1.55B-24.9%
P/E13.6×-1.6×
P/S2.2×-0.9×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Calculated from Harmony Biosciences Holdings, Inc.’s reported figures.

enterprise value/ebitda=5.6×

Based on the most recent quarter.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s EV / EBITDA?
Harmony Biosciences Holdings, Inc. (HRMY) reported EV / EBITDA of 5.6× in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s EV / EBITDA changed year-over-year?
Harmony Biosciences Holdings, Inc.'s EV / EBITDA decreased by 22.9% year-over-year, from 7.3× to 5.6×.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s EV / EBITDA?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s EV / EBITDA has grown at a -38.6% compound annual growth rate (CAGR), from 77.6× to 6.8×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.